Astellas

Astellas builds case for menopause drug fezolinetant
Pharmaphorum
Thu, 11/30/23 - 09:54 am
Astellas
menopause
fezolinetant
Xtandi cleared by FDA for earlier-stage prostate cancer
Pharmaphorum
Fri, 11/17/23 - 10:10 am
Pfizer
Astellas
Xtandi
prostate cancer
FDA
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Fierce Biotech
Thu, 11/16/23 - 11:45 am
Astellas
Propella Therapeutics
M&A
JNJ
Zytiga
prostate cancer
Astellas Sees Path Forward for Gene Therapy Despite Four Patient Deaths
BioSpace
Thu, 11/16/23 - 11:36 am
Astellas
AT132
patient deaths
FDA
X-linked myotubular myopathy
Astellas’ Izervay reduces GA lesion growth in Phase III trial
Clinical Trials Arena
Mon, 11/6/23 - 09:51 am
Astellas
Izervay
geographic atrophy
age-related macular degeneration
clinical trials
A New Drug For Menopausal Hot Flashes, Veozah, Faces Access Challenges
Forbes
Tue, 10/24/23 - 07:49 pm
Astellas
hot flashes
menopause
Veozah
access
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
Fierce Pharma
Wed, 10/18/23 - 11:42 am
Seagen
Astellas
Merck
Padcev
Keytruda
bladder cancer
ESMO
Astellas rolls out national Veozah campaign for treating menopause symptoms
Medical Marketing and Media
Mon, 10/9/23 - 10:04 am
Astellas
Veozah
menopause
hot flashes
TV ads
DTC ads
Patient Death Likely from Virus Used to Deliver Gene-Editing Therapy: NEJM Study
BioSpace
Thu, 09/28/23 - 10:33 am
NEJM
clinical trials
Duchenne Muscular Dystrophy
patient deaths
Astellas
Pfizer
Astellas Withdrew Its Inflation Reduction Act Lawsuit—Will Other Companies Follow?
BioSpace
Wed, 09/27/23 - 11:09 pm
Astellas
legal
Inflation Reduction Act
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
BioSpace
Fri, 09/22/23 - 11:53 am
Merck
Seagen
Astellas
urothelial cancer
clinical trials
bladder cancer
Padcev
Keytruda
Taysha ends work on gene therapy after Astellas walks away, FDA requests randomized trial
Fierce Biotech
Wed, 09/20/23 - 08:47 am
Astellas
Taysha Gene Therapies
gene therapy
FDA
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophy
PR Newswire
Tue, 09/19/23 - 10:28 am
Astellas
clinical trials
Izervay
geographic atrophy
EU clears review of Xtandi in earlier-stage prostate cancer
Pharmaphorum
Wed, 09/13/23 - 06:02 pm
EMA
Europe
Astellas
Pfizer
prostate cancer
Xtandi
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Reuters
Thu, 09/7/23 - 10:44 am
Astellas
Medicare
prostate cancer
Xtandi
drug pricing
Inflation Reduction Act
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
Wed, 08/23/23 - 11:11 am
patent cliff
patents
Takeda
Vyvanse
Pfizer
Eraxis
JNJ
Stelara
Merck
Isentress
Eiger Pharmaceuticals
Zokinvy
Astellas
Myrbetriq
Novartis
Entresto
Amgen
Otzela
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
Wed, 08/16/23 - 10:16 am
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood
PR Newswire
Wed, 08/9/23 - 10:36 pm
Astellas
Cambridge MA
R&D
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
BioPharma Dive
Sun, 08/6/23 - 09:25 pm
Iveric Bio
geographic atrophy
FDA
Izervay
Astellas
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
Sat, 07/29/23 - 10:45 pm
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy

Pages